Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer

Interstitial lung disease (ILD) is a serious and potentially fatal adverse event in lung cancer therapy. Nanoparticle albumin-bound paclitaxel (nab-PTX) is a novel, solvent-free formulation of paclitaxel (PTX). Although the incidence of nab-PTX-induced ILD is not clear, it is generally considered th...

詳細記述

保存先:
書誌詳細
出版年:Case Rep Oncol
主要な著者: Nakatani, Yuki, Nakaya, Aya, Kurata, Takayasu, Yokoi, Takashi, Takeyasu, Yuki, Niki, Maiko, Kibata, Kayoko, Satsutani, Naoko, Ogata, Makoto, Miyara, Takayuki, Nomura, Shosaku
フォーマット: Artigo
言語:Inglês
出版事項: S. Karger AG 2017
主題:
Case Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5582424/
https://ncbi.nlm.nih.gov/pubmed/28878650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000479148
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料